{"filing":{"accession_number":"0001140361-26-028602","cik":"0001104506","ticker":"INSM","company_name":"INSMED Inc","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"ef20078093_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1104506/000114036126028602/ef20078093_8k.htm"},"events":[{"id":18273,"run_id":16423,"accession_number":"0001140361-26-028602","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Insmed announced positive 12-month safety and efficacy data from an ongoing open-label extension study of treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension patients. The disclosure demonstrates sustained clinical improvements across secondary efficacy measures (6MWD, NT-proBNP, WHO Functional Class, REVEAL Lite 2.0 score) and favorable safety profile, supporting advancement to Phase 3 PALM-PAH trial. This is a material clinical milestone for an investigational drug in mid-to-late stage development that would affect investor assessment of the company's pipeline and commercial prospects.","company_name":"INSMED Inc","ticker":"INSM","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17035,"accession_number":"0001140361-26-028602","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Insmed announced positive 12-month safety and efficacy data from an ongoing open-label extension study of treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension patients. The disclosure demonstrates sustained clinical improvements across secondary efficacy measures (6MWD, NT-proBNP, WHO Functional Class, REVEAL Lite 2.0 score) and favorable safety profile, supporting advancement to Phase 3 PALM-PAH trial. This is a material clinical milestone for an investigational drug in mid-to-late stage development that would affect investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:01:43.351917+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17035,"accession_number":"0001140361-26-028602","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Insmed announced positive 12-month safety and efficacy data from an ongoing open-label extension study of treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension patients. The disclosure demonstrates sustained clinical improvements across secondary efficacy measures (6MWD, NT-proBNP, WHO Functional Class, REVEAL Lite 2.0 score) and favorable safety profile, supporting advancement to Phase 3 PALM-PAH trial. This is a material clinical milestone for an investigational drug in mid-to-late stage development that would affect investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:01:43.351917+00:00","company_name":"INSMED Inc","ticker":"INSM","filing_date":"2026-07-16"}]}